On June 5, 2025, TAG and WHO cohosted a webinar orienting people to long-acting injectables for TB treatment and prevention. Long-acting Injectables (LAIs) have the potential to revolutionize treatment for TB and other infectious diseases.
This publication discusses findings from two surveys conducted among end users and healthcare providers/policy makers to understand their perspectives on, and the facilitators and barriers to potential long-acting therapies for Hepatitis C virus (HCV) cure currently being developed by the LONGEVITY consortium, funded by the global health agency Unitaid.
This webinar will provide a platform to learn about the findings from the Longevity HCV and TB end users and healthcare providers/policy makers surveys, and for community members, especially marginalized populations across the world, to engage with the researchers developing these Long-Acting Therapies.
The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB.
To accompany the updated Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis, TAG also developed three additional educational materials to support community-based and civil society organizations leading treatment literacy, peer support, and community-led monitoring activities:
TAG is deeply concerned about the Trump administration’s potential plans to eliminate vital HIV programs at the CDC’s Division of HIV Prevention (DHP) and other programs in the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).
The ACT NOW: END AIDS Coalition (ANEA) and Treatment Action Group (TAG) are proud to stand in solidarity with activists demonstrating today at the U.S. Capitol demanding that the U.S. government restore full funding to the President’s Emergency Plan for AIDS Relief (PEPFAR)
TAG’s Cheat Sheets for Tuberculosis Activists are designed to help advocates navigate the range of tools in use and in the research pipeline.
To help advocates stay up to date, Treatment Action Group (TAG) organized a series of virtual trainings on the diagnosis, treatment, care and support of people with drug-resistant TB, designed for community and civil society organizations.
This year’s edition of TAGline takes stock of the state of the HIV, TB, and HCV pandemics worldwide, and advances bold visions for what a future without them must look like.